化疗及胸腺肽α1对恶性肿瘤患者细胞免疫功能的影响及意义的临床研究

目的探讨化疗及胸腺肽α1对恶性肿瘤患者细胞免疫功能的影响及意义。方法130例恶性肿瘤患者在化疗前一周及化疗2周期后分别检测外周血T细胞亚群（CD3^＋、CD4^＋、CD8^＋）B细胞（CD19^＋）NK细胞（CD3^-／CD16CD56），并比较化疗前后的变化，随后随机分为A、B两组，在其他治疗相同的前提下，A组给予胸腺肽α11．6mg OodIH，2～6个月，B组不用胸腺肽α1治疗，2月后两组均行细胞免疫功能（CD3^＋、CD4^＋、CD8^＋、CD19^＋、CD3^-／CD16-CD56^＋）测定。结果恶性肿瘤患者化疗后细胞免疫功能比较CD3^＋、CD4^＋细胞升高，CD8^＋细胞下降（P〉O．05），CD4^＋／CD8^＋显著升高（P〈0．05）；A组与B组相比A组的CD3^＋、CD4^＋、CD8^＋、CD4^＋／CD8^＋、NK细胞活性较治疗前显著提高（P〈0．05），B组各项指标治疗前后无显著差异（P〉0．05）。结论化疗不会完全破坏机体的免疫功能，而会使部分免疫功能提高及调整；胸腺肽Q1可以提高肿瘤患者的细胞免疫功能，从而增强抑瘤作用。

Clinical Study of Significance on Chemotherapy and Thysomial Immunotherapy in Malignant Carcinoma Patients

Objective To expore the chang and significance between before and after chemotherapy and immunotherapy with immune activited cell in malignant carcinoma patients. Methodes Before and two cycles chemotherapies, 130 patients were tested the immue activity cell （CD3＋. CD4＋, CD8~. CD19^＋. CD4^＋/CD8^＋. CD3^-/CD16^-CD56^＋ ）; Then all patients was divided into two groups, Group A were treated with thysominl 1.6mg Qod IH 2-6个月, Group A were treated with normal therapy, All patients were tested immune activited cell after two moithes. Results CD3^＋. CD4^＋cell in The patients who received chemotherapy were higher , CD8^＋ cell wasreduced （P〉0.05） , CD4^＋/CD 8^＋ cell was significantly higher.the activity ofCD4^＋, CD8^＋ , CD4^＋/CD8^＋. NK cell in group A were significantly higher than groupB. The index in groupB was equal to before treament. Conclusion The emotherapy will not completely destroy the immunity, but will partly increase and modulate the immunity; thysomial can enhance the whole immunity of patients and kill cancer cell.